Meplazumab for Injection + Sterile normal saline (0.9%)
Phase 1Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Malaria (Plasmodium Falciparum)
Conditions
Malaria (Plasmodium Falciparum)
Trial Timeline
Mar 1, 2023 → Mar 1, 2024
NCT ID
NCT04327310About Meplazumab for Injection + Sterile normal saline (0.9%)
Meplazumab for Injection + Sterile normal saline (0.9%) is a phase 1 stage product being developed by Pacific Biosciences for Malaria (Plasmodium Falciparum). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04327310. Target conditions include Malaria (Plasmodium Falciparum).
What happened to similar drugs?
11 of 19 similar drugs in Malaria (Plasmodium Falciparum) were approved
Approved (11) Terminated (1) Active (8)
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04327310 | Phase 1 | Withdrawn |
| NCT05113784 | Phase 2/3 | Completed |
| NCT04586153 | Phase 2/3 | Completed |
Competing Products
20 competing products in Malaria (Plasmodium Falciparum)